Monte Rosa Therapeutics I... (GLUE)

AI Score

Unlock

5.09

-0.17 (-3.23%)

At close: Mar 28, 2025, 3:59 PM

5.12

0.50%

After-hours: Mar 28, 2025, 07:51 PM EDT

-3.23% (1D)

Bid	5.02
Market Cap	313.39M
Revenue (ttm)	75.71M
Net Income (ttm)	-72.79M
EPS (ttm)	-0.98
PE Ratio (ttm)	-5.2
Forward PE	-3.65
Analyst	Buy

Ask	5.19
Volume	492,251
Avg. Volume (20D)	740,130
Open	5.25
Previous Close	5.26
Day's Range	5.03 - 5.27
52-Week Range	3.21 - 12.40
Beta	1.50

About GLUE

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 24, 2021

Employees 134

Stock Exchange NASDAQ

Ticker Symbol GLUE

Website https://www.monterosatx.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 214.03% from the latest price.

Stock Forecasts

Earnings Surprise

Monte Rosa Therapeutics has released their quartely earnings on Mar 20, 2025:

Revenue of $60.65M exceeds estimates by $47.86M, with Infinity% YoY growth.

EPS of 0.23 exceeds estimates by 0.60, with 139.66% YoY growth.

Next Earnings Release

Monte Rosa Therapeutics Inc. is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+93.87%

Monte Rosa Therapeutics shares are trading higher ... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic ...

1 week ago · zacks.com

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year a...

3 weeks ago · zacks.com

3 Top Cancer Biotechs to Keep An Eye On in 2025

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

1 month ago · seekingalpha.com

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partn...